Sipurui Pharmaceutical Technology

About Sipurui Pharmaceutical Technology

Sipurui Pharmaceutical Technology, trading as SciBrunch Therapeutics, is a biotechnology company focused on the research, development, and iterative innovation of small molecule anti-tumor drugs. Founded in 2024 by Dr. Tao Hu and Dr. Yang Zhang, the company is based in Shanghai, China. SciBrunch aims to identify clinically validated targets from new perspectives and design differentiated product features to build a globally competitive pipeline.

The company was co-founded by Dr. Tao Hu, who serves as Chairman and CEO, and Dr. Yang Zhang, the Chief Scientific Officer. Dr. Hu has over two decades of experience in innovative drug R&D, business development, and corporate governance at companies like Merck, Amgen, and WuXi AppTec. Before SciBrunch, he was the co-founder and CEO of Usynova, where he led a global exclusive licensing deal with AstraZeneca in 2023. Dr. Zhang has nearly 20 years of experience in medicinal chemistry and preclinical development of small molecule drugs, previously serving as Vice President at WuXi AppTec. He has led the design of nearly 20 small molecule oncology drugs that are in various stages of clinical development.

SciBrunch's business model is centered on developing a robust pipeline of cancer therapeutics and generating revenue through their provision. The company's pipeline includes a high-penetration PARP1 selective inhibitor (SPR1020) for breast cancer and glioma, and a RAS pathway molecular glue (SPR2015) for pancreatic and lung cancer, among others. In June 2025, SciBrunch announced the completion of an oversubscribed angel funding round of more than 200 million RMB. The financing was co-led by BioTrack Capital and Hankang Capital, with participation from Elikon Venture and LongRiver Investments. These funds are designated for the preclinical and early clinical development of its existing drug candidates.